NPPG Administrator, Suite 213, Boundary House, London W7 2QE
Recent consultations NPPG has responded to as of July 2026
Thank you to our committee members and our specialist interest groups for the comments received on recent consultations.
Since the previous full committee meeting the following consultations have been reviewed:
Consultations
Thank you to our committee members and our specialist interest groups for the comments received on recent consultations and to those who have volunteered to be nominated experts. The following consultations have been reviewed since the September committee meeting:
| 1. | NICE STA Invitation to participate |
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457] | 28/08/2025 | Expert nomination – 30/10/2025 Organisation submission – 30/10/2025 |
Circulated to committee members 01/09/2025 | No comments received. A ‘No comment’ response submitted – 05/11/2025 |
| 2. | NICE STA Draft Scope Consultation |
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446 | 03/09/2025 | Deadline for comments – 01/10/2025 | Circulated to committee members 03/09/2025 | No comments received. A ‘No comment’ response submitted. 01/10/2025 |
| 3. | NICE STA Draft Scope Consultation |
Orforglipron for managing overweight and obesity ID6516 | 04/09/2025 | Deadline for comments – 02/10/2025 | Circulated to committee members 04/09/2025 | No comments received. A ‘No comment’ response submitted. 02/10/2025 |
| 4. | NICE STA Invitation to participate |
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448] | 02/10/2025 | Deadline for comments 04/12/2025 | Circulated to committee members 03/10/2025 | Submitted comments – 04/12/2025 |
| 5. | NICE STA Draft Scope Consultation |
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519 | 04/11/2025 | Deadline for comments 02/12/2025 | Circulated to committee members 04/11/2025 | No comments received. A ‘No comment’ response submitted 02/12/2025 |
| 6. | NICE STA Invitation to participate |
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537] | 04/11/2025 | Deadline for expert nominations and comments is 20/01/2026 | Circulated to committee members 04/11/2025 | No comments received. A ‘No comment’ response submitted 20/01/2026 |
| 7. | NICE STA Invitation to participate |
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458] | 04/11/2025 | Deadline for expert nominations and comments is 20/01/2026 | Circulated to committee members 05/11/2025 | No comments received. A ‘No comment’ response submitted 20/01/2026 |
| 8. | NICE STA invitation to participate |
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510] | 04/11/2025 | Deadline for expert nominations and comments is 20/01/2026 | Circulated to committee members 05/11/2025 | No comments received. A ‘No comment’ response submitted 20/01/2026 |
| 9. | NHS England Highly Specialised Services | Mobile Extracorporeal Membrane Oxygenation (ECMO) for Neonates, Infants & Children | 03/11/2025 | Deadline for feedback 02/12/2025 | Circulated to committee members and Sandra Forbes at Profile – 05/11/2025 | |
| 10. | NICE STA Invitation to participate |
Onasemnogene abeparvovec (intrathecal) [ID6556] | 24/11/2025 | Deadline for expert nominations and organisation submission is 09/02/2026 | Circulated to committee members – 24/11/2025 | Expert nomination form and Appendix B for Satvinder Mahal submitted by PR on 06/01/2026 |
| 11. | NICE STA Invitation to participate |
Myopia (3-14 years) – atropine (low dose, eye drops) [ID6517] | 26/11/2025 | Deadline for expert nominations and organisation submission is 09/02/2026 | Circulated to committee members – 26/11/2025 | No comments received. A ‘No comment’ response submitted – 09/02/2026 |
| 12. | NICE STA Invitation to participate |
Orforglipron for managing overweight and obesity [ID6516] | 01/02/2025 | Deadline for expert nominations and organisation submission is 16/02/2026 | Circulated to committee members – 02/12/2025 | Submitted comments received from Jo Crook – 10/02/2026 |
| 13. | NICE HTE Draft Scope Consultation |
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598] | 01/12/2025 | Deadline for comments 15/12/2025 | Circulated to committee members – 02/12/2025 | No comments received. A ‘No comment’ response submitted 15/12/2025 |
| 14. | NICE STA Invitation to participate |
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446] | 05/12/2025 | Deadline for expert nominations and organisation submission is 20/02/2026 | Circulated to committee members – 08/12/2025 | No comments received. A ‘No comment’ response submitted – 20/02/2026 |
| 15. | NICE STA Draft Scope Consultation |
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400 | 10/12/2025 | Deadline for comments 15/01/2026 | Circulated to committee members – 10/12/2025 | No comments received. A ‘No comment’ response submitted 15/01/2026. |
| 16. | NHS England Highly Specialised Services | High Consequence Infectious Diseases (HCID) Critical Care Transfer Services | 10/12/2025 | Deadline for feedback 09/01/2026 | Circulated to committee members – 11/12/2025 | |
| 17. | NICE STA Draft Scope Consultation |
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542 | 11/12/2025 | Deadline for comments 16/01/2026 | Circulated to committee members – 11/12/2025 | Submitted comments received from Nabil Boulos- 16/01/2026 |
| 18. | NICE Highly Specialised Technology Invitation to participate |
Setmelanotide for treating obesity and hyperphagia in syndrome (review of HST31) [ID6598] | 18/12/2025 | Deadline for expert nominations and organisation submission is 11/02/2026 | Circulated to committee members – 19/12/2025 | |
| 19. | NICE STA Invitation to participate |
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519] | 05/01/2026 | Deadline for expert nomination and comments – 09/03/2026 | Circulated to committee members – 06/01/2026 | |
| 20. | NICE STA Draft Scope Consultation |
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency ID6192 | 21/01/2026 | Deadline for comments – 18/02/2026 | Circulated to committee members – 21/01/2026 | |
| 21. | NICE STA Draft guidance document |
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] | 06/02/2026 | Deadline for comments – 06/03/2026 | Circulated to committee members – 10/02/2026 | |
| 22. | NICE Draft Guideline | Draft guideline on Neonatal infection: antibiotics for prevention and treatment – 19/02/2026 to 04/03/2026 | 19/02/2026 | Deadline for comments 04/03/2026 | Circulated to committee members – 26/02/2026 | |
| 23. | NICE STA Draft Scope Consultation |
Scoping Workshop and Consultation Invitation (All C&C): Mucopolysaccharidosis (type IIIA) – rebisufligene etisparvovec ID6540 | 04/03/2026 | Deadline for comments – 01/04/2026 | Circulated to committee members – 04/03/2026 | |
| 24. | NICE STA Invitation to participate |
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400] | 09/03/2026 | Deadline for expert nomination and comments – 19/05/2026 | Circulated to committee members – 09/03/2026 | |
| 25. | NICE STA Draft Scope Consultation |
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903] | 27/03/2026 | Deadline for comments 28/04/2026 | Circulated to committee members – 27/03/2026 | |
| 26. | NICE STA Draft Scope Consultation |
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757] | 06/05/2026 | Deadline for comments 27/05/2026 | Circulated to committee members – 06/05/2026 | |
| 27. | NICE HST Invitation to participate |
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 and over [ID3903] | 20/05/2026 | Deadline for expert nomination and comments – 16/07/2026 | Circulated to committee members – 21/05/2026 | |
| 28. | NICE STA Draft Scope Consultation |
Semaglutide 7.2 mg dose for managing obesity ID6699 | 28/05/2026 | Deadline for comments 25/06/2026 | Circulated to committee members – 01/06/2026 | |
| 29. | PrescQipp | Registered for 2026-28 work plan stakeholder consultation | 30/04/2026 | Circulated to committee members and collated responses | ||
| 30. | NICE STA Invitation to participate |
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757] | 10/06/2026 | Deadline for expert nomination and comments – 12/08/2026 | Circulated to committee members – 10/06/2026 | Expert nomination for Kalindi Rajani submitted on 23 Jun 2026 – 9:07 by NPPG Information Officer |
CCA – Cost Comparison Appraisal; STA – Single Technology Appraisal; QSU – Quality Standard Update; SpecComm – Specialised Commissioning; MTA – Multiple Technology Appraisal; HTSE – Highly Specialised Technologies Evaluation.